Showing 118 of 118on this page. Filters & sort apply to loaded results; URL updates for sharing.118 of 118 on this page
AZD8233 / Ionis, AstraZeneca
(PDF) AZD8233 antisense oligonucleotide targeting PCSK9 does not ...
AZD8233 antisense oligonucleotide targeting PCSK9 does not prolong QT ...
AZD8233 | PCSK9 siRNA | MedChemExpress
AZD8233 sodium | PCSK9 siRNA | MedChemExpress
AZD8233 reduced low-density lipoprotein cholesterol levels by 73% | The ...
AstraZeneca’s AZD8233 Shows Positive Results for Hypercholesterolemia
AZD8233 reduced low-density lipoprotein cholesterol levels by 73% in ...
Proposed biotransformation pathways of AZD8233. Metabolite profiling ...
In Vivo Metabolite Profiles of an N-Acetylgalactosamine–Conjugated ...
PCSK9丨阿斯利康AZD8233商业化道路崎岖 近日， 阿斯利康 公布了其靶向PCSK9抑制剂AZD8233（ION 449）在 ...
AI辅助一半小分子药物开发，阿斯利康公布最新研发管线（附PPT）_腾讯新闻
医药魔方
精准、长效、安全，小干扰核酸降脂药物最新研究一文读懂！_降低_mg_水平
Abstract 9747: Safety, Pharmacokinetics and Pharmacodynamics of ...
MIDD经典案例3：PCSK9 反义寡核苷酸AZD8233（ION449）项目FIH到III期的量化决策 - 知乎
Table 1 from In Vivo Metabolite Profiles of a GalNAc Conjugated ...
(PDF) In Vivo Metabolite Profiles of a GalNAc Conjugated Antisense ...
口服PCSK9抑制剂，有戏了？阿斯利康发布PCSK9反义疗法最新研究成果 | Science子刊 - 知乎
AZD8233: a liver-targeted antisense oligonucleotide | American Society ...
MNC药企纷纷布局：口服PCSK9抑制剂的时代或将来临 - 知乎
Quantitative relationship between PCSK9 and LDL‐C. Mean digitized ...
What are PCSK9 inhibitors and how do you quickly get the latest ...
臨床試驗新突破：AZD8233顯著降低壞膽固醇與Lp(a)風險因子
AZD8233在ETESIAN IIb期试验中使高危高胆固醇血症患者的低密度脂蛋白胆固醇水平降低了73%医药新闻-ByDrug-一站式医药资源 ...
Population pharmacokinetics of a novel PCSK9 antisense oligonucleotide ...
PCSK9: 心血管疾病治疗的明星靶点 - 知乎
罕见病信息网
AZD0780 | Inhibitor | TargetMol
剑指心血管疾病——小核酸药物(二)|心血管疾病|胆固醇|核酸|药物|靶向|-健康界
新型 PCSK9 反义寡核苷酸的群体药代动力学,British Journal of Clinical Pharmacology - X-MOL
Table 1 from Identification of GalNAc-Conjugated Antisense ...
A Case Study of Model‐Informed Drug Development of a Novel PCSK9 ...
AD8232芯片电路Auto Designer设计与构建-CSDN博客
AD9833BRMZ中文资料_最新报价_数据手册下载_ADI(亚德诺)-直接数字频率合成(DDS)-立创商城
PCSK9 | 前蛋白转化酶/枯草溶菌素9 | 抑制剂 | MCE
中金：核酸药物，时代已至_凤凰网
美国FDA批准阿斯利康哮喘按需治疗急救药物Airsupra|药物|批准|治疗|试验|-健康界
Препарат от холестерина от AstraZeneca и Ionis не перейдет в фазу 3 КИ ...
AstraZeneca's next-generation PCSK9 inhibitor in limbo after latest mid ...
(PDF) An oral antisense oligonucleotide for PCSK9 inhibition
PCSK9竞争格局：单抗、siRNA、小分子、CRISPR PCSK9的药物研发竞争充满了故事性......二十世纪70年代，他汀药物的发现为 ...
中金：核酸药物，时代已至_临床
(PDF) Population pharmacokinetics of a novel PCSK9 antisense ...
2022 年 8 月药企「弹药填充」榜单出炉！
Familial Hypercholesterolemia: JACC Focus Seminar 4/4 | JACC
信达生物PCSK-9抑制剂获批上市，国产化进程加速 - 知乎
信达完成国内首报，PCSK9单抗进退两难|PCSK9|胆固醇血症|首报|信达|国内|单抗|药物|水平|汀类|患者|安进|降低|上市|-健康界
Advances in Oral Biomacromolecule Therapies for Metabolic Diseases
口服PCSK9抑制剂，有戏了？【阿斯利康】发布PCSK9反义疗法最新研究成果 | Science子刊 PCSK9（前蛋白转化酶枯草杆菌蛋白酶 ...
AstraZeneca, Ionis drop hypercholesterolemia candidate despite positive ...
Targeting PCSK9 as a key player in lipid metabolism: exploiting the ...
阿斯利康：1类化药AZD5718片报临床，用于冠状动脉疾病|AZD|FLAP|冠状动脉|白三烯|临床|-健康界
PCSK9的无限可能：口服终生降血脂、联合PD-1抗肿瘤 PCSK9抗体与他汀相比，阻挡其创造业绩神话的一个是价格，一个是便捷性。近期，有关 ...
降脂新靶点PCSK9 - 知乎
速递 | 降低坏胆固醇73%，反义寡核苷酸疗法2b期临床结果积极_康德_剂量_治疗
Antisense Oligonucleotide Therapies
AstraZeneca's Promising Cholesterol Pill: A Game Changer in the Race ...
Amgen eyes swift move to ph3 for cardiovascular drug olpasiran ...
AstraZeneca shares positive results for its drug to lower cholesterol
AstraZeneca dumps Ionis drug despite hit in phase 2 cholesterol trial ...
AZ-아이오니스, 'PCSK9 ASO' 2b상 “LDL-C 최대79%↓” - 바이오스펙테이터
[단독] 새로운 고콜레스테롤혈증 치료제 ‘ION449’ 2상에서 효능 입증 - 헬스코리아뉴스
靶向PCSK9！阿斯利康/Ionis公司反义寡核苷酸疗法在中国获批临床 @药明康德 内容团队报道今日（3月10日），中国国家药监局药品审评中心 ...
PCSK9 反义寡核苷酸疗法！阿斯利康降脂药国内获批临床_Insight_药物_胆固醇
Antisense Oligonucleotide-Based Therapy of Viral Infections
CAS No.93550-62-0 | chem960.com
君实、康方新药获批，如何冲击外资超100%的增长_他汀_降脂_上市
Ionis and AstraZeneca advance first generation 2.5 LICA... | CPHI Online
The translational potential of miR-26 in atherosclerosis and ...
阿斯利康放弃在美国申报新冠疫苗，终止多个项目开发医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
(PDF) A Case Study of Model-Informed Drug Development of a Novel PCSK9 ...
“开门红”小核酸时代将开启？热门靶点、国内企业管线布局早知道|适应症|罕见病|核酸|布局|企业|热门|-健康界
AZ, 中콜레스젠과 옵션딜..“新기전 고지혈증 약물” - 바이오스펙테이터
MNC放弃40余个管线项目：ADC、CAR-T、RNA、小分|管线|药物|抑制剂|项目|一款|-健康界
速递｜降低坏胆固醇73％，反义寡核苷酸疗法2b期临床结果积极_腾讯新闻
君实、康方新药获批，如何冲击外资超100%的增长医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
